Advocates for HIV prevention are calling a newly approved injectable medication a major step in eliminating the spread of the ...

Kenya is one of nine African countries selected for the initial rollout of lenacapavir (LEN), a new injectable drug for human ...

Gilead Sciences is a fantastic company that's revolutionized the treatment of numerous diseases. But click here to read why ...

Walgreens Specialty Pharmacy has expanded its limited distribution drug (LDD) network to now include 265 products, placing it ...

Shares of Gilead Sciences, Inc. (GILD) gained 7.3% after the company reported solid results for the second quarter of 2025 ...

Access is the central tenet to the success of lenacapavir as a form of preexposure prophylaxis (PrEP), according to Jeremiah Johnson, the executive director of PrEP4All and Mitchell Warren, the ...

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Lenacapavir Injection Market size & share revenue was valued at ...

The approval recommendation for lenacapavir is supported by solid Phase 3 data from the PURPOSE 1 and 2 studies. PURPOSE 1 ...

In a major advancement for global HIV prevention, the World Health Organisation (WHO) has officially recommended injectable ...

Walgreens Specialty Pharmacy, which earned $25.9 billion last year from U.S. prescription revenue, has expanded its limited distribution drug portfolio to 265 medications, the company said Aug. 19. ...

An entire session at the 13th International AIDS Society Conference on HIV Science (IAS 2025) in Kigali, Rwanda was devoted to the PURPOSE 1 and PURPOSE 2 studies of the six-monthly injectable PrEP ...

Investing.com -- Gilead Sciences (NASDAQ: GILD) announced Friday that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion ...